BUY
Johnson & Johnson
They have a best in class pharma business. They will spin out their consumer business. Careful with their quarter tomorrow because the strong USD will hit them, but this is temporary.
biotechnology / pharmaceutical
COMMENT
Johnson & Johnson
A fine, long-term story but shares were hammered today when the CEO announced aggressive numbers that the street doubted. Nearly all healthcare stocks sold off, too.
biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson
So many things going for it. New CEO, really trying to put more emphasis on the medical business. One of 2 companies in the world with a AAA credit rating. Resurgence in medical procedures. A play on demographics, Covid rebound, and higher margin businesses. Yield is 2.54%. (Analysts’ price target is $182.15)
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Johnson & Johnson
(A Top Pick Oct 20/22, Up 7.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ is progressing well. To remain disciplined, we recommend trailing up the stop to $166 at this time.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Johnson & Johnson
Stockchase Research Editor: Michael O'Reilly JNJ is a defensive holding that is trading below peer valuation (23x earnings vs 36x for peers). The company is preparing to spin off its consumer division in favour of more investment into its pharmaceutical and medical device divisions. It is reportedly making progress on a ground breaking ulcerative colitis treatment. We recommend placing a stop at $150, looking to achieve $190 -- upside over 15%. Yield 2.7% (Analysts’ price target is $187.82)
biotechnology / pharmaceutical
HOLD
Johnson & Johnson
In process of spinning off consumer products, could lead to value accretion. At lower end of 52-week range, growth has slowed down from historic levels and this gives him pause. Middle valuation among older line pharma. "Blue chip" of pharma industry. He's OK with it, but his pick for portfolios is ELV.
biotechnology / pharmaceutical
BUY
Johnson & Johnson
Continue to like the business. Spinoff of consumer business is a good move. Established business with good prospects. Is a good defensive name(high dividend) for long term investors. Will continue to hold.
biotechnology / pharmaceutical
BUY
Johnson & Johnson
Healthcare is defensive because you have constant demand for these products and services. Investors should have exposure in this uncertain economy. Her pick here is JNJ, given its strong balance sheet. They offer pharmaceuticals, medical devices and consumer products, so are diversified. Aging demographics will fuel demand.
biotechnology / pharmaceutical
BUY
Johnson & Johnson
JNJ vs. PFE Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
biotechnology / pharmaceutical
PAST TOP PICK
Johnson & Johnson
(A Top Pick Sep 16/21, Up 3%) A solid return, considering the year we had. 60 years of consecutive dividend increases. Look at the spinout that's coming. Growth should accelerate. Long term story, not a trade story.
biotechnology / pharmaceutical
BUY
Johnson & Johnson
Great company with limited downside, but more possible upside because of its pending break-up. JNJ will get into regular generic drugs which offers growth.
biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson
She likes healthcare for being a defensive growth sector. JNJ's balance sheet is very strong, so lots of money to buy companies and grow. They spend a lot on R&D. 70% of revenues come from products that rank #1 or 2. 25% of revenues are from products launched within 5 years. Boasts powerful brands across all segments. Their pharma division is doing well, comprising 55% of company revenues. Drugs coming off-patent can be replaced by 14 drugs totaling a potential $5 billion in sales. They pay a 2.7% dividend they has been increasing for 60 straight years. (Analysts’ price target is $186.88)
biotechnology / pharmaceutical
BUY
Johnson & Johnson
Has a great balance sheet and is smart by breaking itself up.
biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson
Giant in pharma. Also medical and consumer. Likes pharma, as it's large and has scale. Patents are more insulated from cliffs than its peers. Well staggered expiry dates, diversified components. Spinoff of consumer division should unlock value. Outperformed S&P 500 in 5/6 of the last bear markets. Undemanding 17x earnings. Yield is 2.66%. (Analysts’ price target is $188.56)
biotechnology / pharmaceutical
BUY
Johnson & Johnson
It reports Tuesday a transitional quarter. JNJ is breaking into a slower-growth consumer products business, and a higher-growth pharma and medical device division. He expects good numbers even in the interim now.
biotechnology / pharmaceutical
Showing 1 to 15 of 539 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 20

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 22

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 22 stock analysts published opinions about JNJ-N. 20 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

22 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2023-01-27, Johnson & Johnson (JNJ-N) stock closed at a price of $168.23.